[go: up one dir, main page]

WO2008102855A1 - 軟骨疾患治療用組成物 - Google Patents

軟骨疾患治療用組成物 Download PDF

Info

Publication number
WO2008102855A1
WO2008102855A1 PCT/JP2008/052999 JP2008052999W WO2008102855A1 WO 2008102855 A1 WO2008102855 A1 WO 2008102855A1 JP 2008052999 W JP2008052999 W JP 2008052999W WO 2008102855 A1 WO2008102855 A1 WO 2008102855A1
Authority
WO
WIPO (PCT)
Prior art keywords
cartilage
composition
effect
treatment
inflammation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/052999
Other languages
English (en)
French (fr)
Inventor
Norimasa Iwasaki
Akio Minami
Yasuhiko Kasahara
Tatsuya Igarashi
Daisuke Kawamura
Fumiyoshi Kasahara
Chihiro Miyajima
Nobuo Ohzawa
Mariko Imai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hokkaido University NUC
Mochida Pharmaceutical Co Ltd
Original Assignee
Hokkaido University NUC
Mochida Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hokkaido University NUC, Mochida Pharmaceutical Co Ltd filed Critical Hokkaido University NUC
Priority to MX2009008760A priority Critical patent/MX2009008760A/es
Priority to EP17157935.2A priority patent/EP3189859B8/en
Priority to KR1020097016862A priority patent/KR101440170B1/ko
Priority to CA2677436A priority patent/CA2677436C/en
Priority to AU2008217916A priority patent/AU2008217916B2/en
Priority to EP08720791.6A priority patent/EP2127687B1/en
Priority to BRPI0807739-8A priority patent/BRPI0807739B1/pt
Priority to NZ578985A priority patent/NZ578985A/en
Priority to JP2009500239A priority patent/JP4740369B2/ja
Priority to US12/311,426 priority patent/US8372394B2/en
Priority to ES08720791.6T priority patent/ES2637163T3/es
Priority to CN200880004925.6A priority patent/CN101951969B/zh
Priority to ES08792674T priority patent/ES2427730T3/es
Priority to NZ584869A priority patent/NZ584869A/en
Priority to AU2008315175A priority patent/AU2008315175B2/en
Priority to BRPI0818719A priority patent/BRPI0818719B1/pt
Priority to CA2703158A priority patent/CA2703158C/en
Priority to MX2010004484A priority patent/MX2010004484A/es
Priority to KR1020107011185A priority patent/KR101510494B1/ko
Priority to JP2009537986A priority patent/JP5491866B2/ja
Priority to CN2008801128819A priority patent/CN101835501B/zh
Priority to EP08792674.7A priority patent/EP2210621B1/en
Priority to PCT/JP2008/065065 priority patent/WO2009054181A1/ja
Publication of WO2008102855A1 publication Critical patent/WO2008102855A1/ja
Priority to IL200342A priority patent/IL200342A/en
Anticipated expiration legal-status Critical
Priority to US13/737,171 priority patent/US9216201B2/en
Priority to IL230335A priority patent/IL230335A/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/734—Alginic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/20—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
    • A61L27/3843—Connective tissue
    • A61L27/3852—Cartilage, e.g. meniscus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/06—Materials or treatment for tissue regeneration for cartilage reconstruction, e.g. meniscus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Botany (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)

Abstract

　本発明は、実質的に炎症、または発熱を惹起しない程度にエンドトキシンレベルを低下させたアルギン酸の１価金属塩を有効成分として含有することを特徴とする、軟骨再生用又は軟骨疾患治療用組成物を提供する。これにより、軟骨再生作用及び軟骨損傷部への適用し易さをより改善した軟骨再生用組成物、ならびに、軟骨を機械的刺激より保護する効果、磨耗や炎症による軟骨の変性変化を抑制する効果、軟骨損傷部を修復させる効果、および、関節組織の炎症や疼痛を抑制する効果を併せもつ軟骨疾患治療用組成物が提供できる。
PCT/JP2008/052999 2007-02-21 2008-02-21 軟骨疾患治療用組成物 Ceased WO2008102855A1 (ja)

Priority Applications (26)

Application Number Priority Date Filing Date Title
MX2009008760A MX2009008760A (es) 2007-02-21 2008-02-21 Composicion para el tratamiento de enfermedades del cartilago.
EP17157935.2A EP3189859B8 (en) 2007-02-21 2008-02-21 Composition for treatment of cartilage disease
KR1020097016862A KR101440170B1 (ko) 2007-02-21 2008-02-21 연골 질환 치료용 조성물
CA2677436A CA2677436C (en) 2007-02-21 2008-02-21 Composition for treatment of cartilage disease
AU2008217916A AU2008217916B2 (en) 2007-02-21 2008-02-21 Composition for treatment of cartilage disease
EP08720791.6A EP2127687B1 (en) 2007-02-21 2008-02-21 Composition for treatment of cartilage disease
BRPI0807739-8A BRPI0807739B1 (pt) 2007-02-21 2008-02-21 Composição para o tratamento de doenças da cartilagem
NZ578985A NZ578985A (en) 2007-02-21 2008-02-21 Composition for treatmet of cartilage disease comprising a monovalent metal salt of alginic acid
JP2009500239A JP4740369B2 (ja) 2007-02-21 2008-02-21 軟骨疾患治療用組成物
US12/311,426 US8372394B2 (en) 2007-02-21 2008-02-21 Compositions and methods for treating cartilage disease
ES08720791.6T ES2637163T3 (es) 2007-02-21 2008-02-21 Composición de tratamiento de condropatías
CN200880004925.6A CN101951969B (zh) 2007-02-21 2008-02-21 用于治疗软骨疾病的组合物
EP08792674.7A EP2210621B1 (en) 2007-10-24 2008-08-19 Composition for the treatment of rheumatoid arthritis
ES08792674T ES2427730T3 (es) 2007-10-24 2008-08-19 Composición para el tratamiento de la artritis reumatoide
AU2008315175A AU2008315175B2 (en) 2007-10-24 2008-08-19 Composition for treatment of joint disease
BRPI0818719A BRPI0818719B1 (pt) 2007-10-24 2008-08-19 composição para o tratamento de doença articular
CA2703158A CA2703158C (en) 2007-10-24 2008-08-19 Composition for treatment of joint disease
MX2010004484A MX2010004484A (es) 2007-10-24 2008-08-19 Composicion para tratamiento de enfermedad de las articulaciones.
KR1020107011185A KR101510494B1 (ko) 2007-10-24 2008-08-19 관절 질환 치료용 조성물
JP2009537986A JP5491866B2 (ja) 2007-10-24 2008-08-19 関節疾患治療用組成物
CN2008801128819A CN101835501B (zh) 2007-10-24 2008-08-19 关节疾病治疗用组合物
NZ584869A NZ584869A (en) 2007-10-24 2008-08-19 Composition for treatment of joint disease
PCT/JP2008/065065 WO2009054181A1 (ja) 2007-10-24 2008-08-19 関節疾患治療用組成物
IL200342A IL200342A (en) 2007-02-21 2009-08-11 A drug used to treat cartilage disease
US13/737,171 US9216201B2 (en) 2007-02-21 2013-01-09 Method for regenerating hyaline cartilage
IL230335A IL230335A (en) 2007-02-21 2014-01-06 A drug used to treat cartilage disease

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2007041520 2007-02-21
JP2007-041520 2007-02-21
JP2007277005 2007-10-24
JP2007-277005 2007-10-24

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/311,426 A-371-Of-International US8372394B2 (en) 2007-02-21 2008-02-21 Compositions and methods for treating cartilage disease
US13/737,171 Division US9216201B2 (en) 2007-02-21 2013-01-09 Method for regenerating hyaline cartilage

Publications (1)

Publication Number Publication Date
WO2008102855A1 true WO2008102855A1 (ja) 2008-08-28

Family

ID=39710126

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/052999 Ceased WO2008102855A1 (ja) 2007-02-21 2008-02-21 軟骨疾患治療用組成物

Country Status (13)

Country Link
US (2) US8372394B2 (ja)
EP (2) EP3189859B8 (ja)
JP (2) JP4740369B2 (ja)
KR (1) KR101440170B1 (ja)
CN (2) CN101951969B (ja)
AU (1) AU2008217916B2 (ja)
BR (1) BRPI0807739B1 (ja)
CA (2) CA2912930C (ja)
ES (1) ES2637163T3 (ja)
IL (2) IL200342A (ja)
MX (1) MX2009008760A (ja)
NZ (2) NZ596105A (ja)
WO (1) WO2008102855A1 (ja)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012512846A (ja) * 2008-12-19 2012-06-07 セリェリクス、ソシエダッド、アノニマ 脂肪幹細胞を含んでなる組成物
WO2013027854A1 (ja) * 2011-08-23 2013-02-28 持田製薬株式会社 軟骨再生用組成物
EP2965751A1 (en) * 2004-10-08 2016-01-13 Forward Pharma A/S Controlled release pharmaceutical compositions comprising a fumaric acid ester
WO2017043485A1 (ja) 2015-09-07 2017-03-16 持田製薬株式会社 アルギン酸凍結乾燥製剤
WO2017163603A1 (ja) 2016-03-23 2017-09-28 国立大学法人北海道大学 椎間板治療用組成物
WO2018159768A1 (ja) 2017-03-02 2018-09-07 持田製薬株式会社 線維軟骨組織損傷治療用組成物
WO2018164128A1 (ja) 2017-03-07 2018-09-13 持田製薬株式会社 アルギン酸液剤
WO2019182015A1 (ja) 2018-03-22 2019-09-26 持田製薬株式会社 非ステロイド性抗炎症性化合物結合アルギン酸誘導体
WO2021145404A1 (ja) * 2020-01-17 2021-07-22 持田製薬株式会社 骨髄液を用いた軟骨損傷治療材
JP2021109006A (ja) * 2020-01-14 2021-08-02 持田製薬株式会社 注入装置
US12491208B2 (en) 2020-01-14 2025-12-09 Mochida Pharmaceutical Co., Ltd. Combination and method for treating subject using alginate

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ596105A (en) * 2007-02-21 2012-08-31 Mochida Pharm Co Ltd Composition for treatmet of cartilage disease comprising a monovalent metal salt of alginic acid and bone marrow mesenchymal stem cells
WO2011031642A2 (en) * 2009-09-08 2011-03-17 Musculoskeletal Transplant Foundation Inc. Tissue engineered meniscus repair composition
WO2011031637A2 (en) * 2009-09-08 2011-03-17 Musculoskeletal Transplant Foundation Inc. Tissue engineered meniscus repair composition
WO2012085609A1 (en) * 2010-12-20 2012-06-28 Dept. Of Pathobiology Treatment of osteoarthritis by continuous intra-articular injection of alginate gel
US10016527B2 (en) * 2012-10-23 2018-07-10 Orthovita, Inc. Materials and methods for repair of cartilage defects
US9616093B2 (en) * 2013-01-30 2017-04-11 NuTech Medical, Inc. Placental membrane preparation and methods of making and using same
US10563108B2 (en) * 2014-04-24 2020-02-18 National University Corporation Hokkaido University Latent heat storage body, method for producing latent heat storage body and heat exchange material
JP2017518315A (ja) * 2014-06-06 2017-07-06 ヴィヴォスクリプト，インコーポレイテッド 軟骨損傷を修復する方法
GB201412236D0 (en) * 2014-07-09 2014-08-20 Univ Nottingham Method of producing and using alginate hydrogels
WO2016073989A2 (en) * 2014-11-07 2016-05-12 The Trustees Of Columbia University In The City Of New York Osteochondroreticular stem cells for bone and cartilage regeneration
CN106344595B (zh) * 2015-07-17 2020-06-19 上海绿谷制药有限公司 褐藻胶寡糖及其衍生物在制备治疗疼痛药物中的应用
EP3506946A1 (en) * 2016-09-05 2019-07-10 Association for the Advancement of Tissue Engineering and Cell based Technologies & Therapies (A4TEC) - Associação Kefiran for use in regenerative medicine and/or tissue engineering
US11872328B2 (en) * 2017-08-30 2024-01-16 Hadasit Medical Research Services And Development Ltd. Devices, kits and methods for reducing and/or preventing intra-abdominal adhesions
US11406612B2 (en) 2018-02-26 2022-08-09 Rensselaer Polytechnic Institute Method of treatment via intra-articular application of potassium
JPWO2020045162A1 (ja) * 2018-08-30 2021-08-12 学校法人慶應義塾 薬物送達用担体
ES3043132T3 (en) * 2019-08-01 2025-11-24 Medicrinia Co Ltd Composition comprising hyaluronic acid and pluronic for preventing or treating articular and cartilage injury
KR102587871B1 (ko) * 2020-06-19 2023-10-12 숙명여자대학교산학협력단 Bmpr2 유전자 기능획득 돌연변이체를 포함하는 돌연변이 복합체 및 이의 용도
JPWO2022102093A1 (ja) 2020-11-13 2022-05-19
WO2024136537A1 (ko) * 2022-12-23 2024-06-27 주식회사 삼양홀딩스 조직 수복용 건조 제형

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0513136A (ja) 1991-06-28 1993-01-22 Nec Corp Ｉｃソケツト
JPH08269102A (ja) 1995-03-30 1996-10-15 Shiseido Co Ltd エンドトキシンフリーのβ１，３−グルカン及びその製造法並びに医療用ゲル素材
US5589591A (en) 1986-07-03 1996-12-31 Advanced Magnetics, Inc. Endotoxin-free polysaccharides
JPH09324001A (ja) 1996-04-02 1997-12-16 Kyowa Hakko Kogyo Co Ltd ヒアルロン酸ナトリウムの精製法
JPH10101577A (ja) * 1996-09-27 1998-04-21 Nikken Chem Co Ltd 関節可動域低下症の予防・治療薬
WO2002055073A1 (en) * 2001-01-05 2002-07-18 Kyowa Kakko Kogyo Co., Ltd. Preventives for arthritis
JP2002530440A (ja) 1998-11-13 2002-09-17 シーピー ケルコ ユー．エス．インク． エンドトキシンレベルが低い生体高分子塩、その生体高分子組成物およびこれを製造する方法
WO2003099339A1 (fr) * 2002-05-29 2003-12-04 Anges Mg, Inc. Composition leurre pour traiter et prevenir une affection inflammatoire
JP2005036036A (ja) 2003-07-16 2005-02-10 Tanabe Seiyaku Co Ltd エンドトキシン除去方法
WO2006044342A2 (en) 2004-10-12 2006-04-27 Fmc Biopolymer As Self-gelling alginate systems and uses thereof
JP2007041520A (ja) 2005-07-29 2007-02-15 Optimax Technology Corp 光学補償膜の製造方法及び光学補償膜を具有する偏光板
JP2007075425A (ja) * 2005-09-15 2007-03-29 Mochida Pharmaceut Co Ltd アルギン酸を含む創傷被覆材
JP2007277005A (ja) 2006-03-17 2007-10-25 Kyocera Mita Corp 画像形成装置

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3379868D1 (en) * 1983-07-11 1989-06-22 Donald E Burg Flexible bow seal air ride boat hull
WO1993013136A1 (en) 1991-12-20 1993-07-08 Howmedica Inc. Ultra-pure polysaccharide materials for medical use
US5266326A (en) * 1992-06-30 1993-11-30 Pfizer Hospital Products Group, Inc. In situ modification of alginate
JP4002299B2 (ja) * 1996-12-10 2007-10-31 セラマット・インコーポレーテッド 組織処理用の改善されたヒドロゲル
EP1015042A1 (en) * 1997-09-19 2000-07-05 Reprogenesis, Inc Improved hydrogel for tissue engineering
TW200307011A (en) * 2002-04-18 2003-12-01 Chugai Pharmaceutical Co Ltd Hyaluronic acid modifier
NZ596105A (en) * 2007-02-21 2012-08-31 Mochida Pharm Co Ltd Composition for treatmet of cartilage disease comprising a monovalent metal salt of alginic acid and bone marrow mesenchymal stem cells

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589591A (en) 1986-07-03 1996-12-31 Advanced Magnetics, Inc. Endotoxin-free polysaccharides
JPH0513136A (ja) 1991-06-28 1993-01-22 Nec Corp Ｉｃソケツト
JPH08269102A (ja) 1995-03-30 1996-10-15 Shiseido Co Ltd エンドトキシンフリーのβ１，３−グルカン及びその製造法並びに医療用ゲル素材
JPH09324001A (ja) 1996-04-02 1997-12-16 Kyowa Hakko Kogyo Co Ltd ヒアルロン酸ナトリウムの精製法
JPH10101577A (ja) * 1996-09-27 1998-04-21 Nikken Chem Co Ltd 関節可動域低下症の予防・治療薬
JP2002530440A (ja) 1998-11-13 2002-09-17 シーピー ケルコ ユー．エス．インク． エンドトキシンレベルが低い生体高分子塩、その生体高分子組成物およびこれを製造する方法
WO2002055073A1 (en) * 2001-01-05 2002-07-18 Kyowa Kakko Kogyo Co., Ltd. Preventives for arthritis
WO2003099339A1 (fr) * 2002-05-29 2003-12-04 Anges Mg, Inc. Composition leurre pour traiter et prevenir une affection inflammatoire
JP2005036036A (ja) 2003-07-16 2005-02-10 Tanabe Seiyaku Co Ltd エンドトキシン除去方法
WO2006044342A2 (en) 2004-10-12 2006-04-27 Fmc Biopolymer As Self-gelling alginate systems and uses thereof
JP2007041520A (ja) 2005-07-29 2007-02-15 Optimax Technology Corp 光学補償膜の製造方法及び光学補償膜を具有する偏光板
JP2007075425A (ja) * 2005-09-15 2007-03-29 Mochida Pharmaceut Co Ltd アルギン酸を含む創傷被覆材
JP2007277005A (ja) 2006-03-17 2007-10-25 Kyocera Mita Corp 画像形成装置

Non-Patent Citations (22)

* Cited by examiner, † Cited by third party
Title
"Tokyo Medical and Dental University", MARUZEN CO., LTD., pages: 235 - 243
APPL. MICROBIOL. BIOTECHNOL., vol. 40, 1994, pages 638 - 643
CAY M. MIERISCH ET AL.: "Transforming Growth Factor (3 in Calcium Alginate Beads for the Treatment of Articular Cartilage Defects in the Rabbit", THE JOURNAL OF ARTHROSCOPIC AND RELATED SURGERY, vol. 18, no. 8, October 2002 (2002-10-01), pages 892 - 900
CHIKAKO YOMOTA ET AL., BULL. NATL. HEALTH SCI., vol. 117, 1999, pages 135 - 139
CHIKAKO YOMOTA ET AL., BULL. NATL. HEALTH SCI., vol. 121, 2003, pages 30 - 33
CHOJI SHIMIZU ET AL., J. RHEUMATOL., vol. 25, 1998, pages 1813 - 1819
DAVID R. DIDUCH ET AL.: "Chondrocyte Transplantation into Articular CartilageDefects with Use of Calcium Alginate: The Fate of the Cells", J BONE JOINT SURG.AM, vol. 85, 2003, pages 1757 - 1767
DAVID R. DIDUCH ET AL.: "Marrow Stromal Cells Embedded in Alginate for Repair of Osteochondral Defects", THE JOURNAL OF ARTHROSCOPIC AND RELATED SURGERY, vol. 16, no. 6, September 2000 (2000-09-01), pages 571 - 577
E. FRAGONAS ET AL.: "Articular Cartilage Repair in Rabbits by Using Suspensions of Allogenic Chondrocytes in Alginate", BIOMATERIALS, vol. 21, 2000, pages 795 - 801, XP004196854, DOI: doi:10.1016/S0142-9612(99)00241-0
FRAGONAS E. ET AL.: "Articular cartilage repair in rabbits by using suspensions of allogenic chondrocytes in alginate", BIOMATERIALS, vol. 21, 2000, pages 795 - 801, XP004196854 *
GABRIELE, G. ET AL., BIOMATERIAL, vol. 21, 2000, pages 2561 - 2574
HOSHIKAWA A. ET AL.: "OA to Bioengineerng", IGAKU NO AYUMI, vol. 211, no. 4, 2004, pages 269 - 273, XP008110925 *
IGARASHI T. ET AL.: "Nankotsu Saisei ni Muketa Kokasei Kojundo Tei-Endotoxin Alginic Acid Gel o Mochiita Shinki Ishoku System no Kaihatsu", J. JPN. ORTHOP. ASSOC., vol. 81, no. 8, 2007, pages S838, XP008110924 *
KEITH T. PAIGE ET AL.: "De Novo Cartilage Generation Using Calcium Alginate-Chondrocyte Constructs", PLASTIC AND RECONSTRUCTIVE SURGERY, vol. 97, 1996, pages 168 - 178
MATSUMINE A. ET AL.: "3. Hone Nankotsu no Saisei . Shufuku - Rinsho Oyo eno Tenbo", EXPERIMENTAL MEDICINE, vol. 20, 2002, pages 2569 - 2574, XP008110917 *
SCIENCE, vol. 122, 1952, pages 501
See also references of EP2127687A4
SHIZUHIKO IHARA ET AL., FOLIA PHARMACOL. JAPON, vol. 100, 1992, pages 359 - 365
THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, vol. 199, 1967, pages 519
TOSHIYUKI KIKUCHI ET AL.: "to evaluate effects of the administered drugs", OSTEOARTHRITIS AND CARTILAGE, vol. 4, 1996, pages 99 - 110
VIGNON, E. ET AL.: "Histological cartilage changes in a rabbit model of osteoarthritis", J. RHEUMATOL., vol. 14, 1987, pages 104 - 6
VIROLOGY, vol. 8, 1959, pages 396

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2965751A1 (en) * 2004-10-08 2016-01-13 Forward Pharma A/S Controlled release pharmaceutical compositions comprising a fumaric acid ester
JP2012512846A (ja) * 2008-12-19 2012-06-07 セリェリクス、ソシエダッド、アノニマ 脂肪幹細胞を含んでなる組成物
JPWO2013027854A1 (ja) * 2011-08-23 2015-03-23 持田製薬株式会社 軟骨再生用組成物
WO2013027854A1 (ja) * 2011-08-23 2013-02-28 持田製薬株式会社 軟骨再生用組成物
US9821027B2 (en) 2011-08-23 2017-11-21 Mochida Pharmaceutical Co., Ltd. Method for regenerating cartilage comprising applying a monovalent metal salt of alginic acid and SDF-1
WO2017043485A1 (ja) 2015-09-07 2017-03-16 持田製薬株式会社 アルギン酸凍結乾燥製剤
JP7020913B2 (ja) 2015-09-07 2022-02-16 持田製薬株式会社 アルギン酸凍結乾燥製剤
KR20180040158A (ko) 2015-09-07 2018-04-19 모찌다 세이야쿠 가부시끼가이샤 알긴산 동결 건조 제제
JPWO2017043485A1 (ja) * 2015-09-07 2018-08-16 持田製薬株式会社 アルギン酸凍結乾燥製剤
US12151025B2 (en) 2015-09-07 2024-11-26 Mochida Pharmaceutical Co., Ltd. Freeze-dried alginic acid preparation
JP2022048356A (ja) * 2015-09-07 2022-03-25 持田製薬株式会社 アルギン酸凍結乾燥製剤
US10966929B2 (en) 2015-09-07 2021-04-06 Mochida Pharmaceutical Co., Ltd. Freeze-dried alginic acid preparation
JP7367089B2 (ja) 2015-09-07 2023-10-23 持田製薬株式会社 アルギン酸凍結乾燥製剤
WO2017163603A1 (ja) 2016-03-23 2017-09-28 国立大学法人北海道大学 椎間板治療用組成物
EP4374886A1 (en) 2016-03-23 2024-05-29 National University Corporation Hokkaido University Composition for treating intervertebral disc
JP2019088900A (ja) * 2016-03-23 2019-06-13 国立大学法人北海道大学 椎間板治療用組成物
JPWO2017163603A1 (ja) * 2016-03-23 2019-01-31 国立大学法人北海道大学 椎間板治療用組成物
JP2023134610A (ja) * 2016-03-23 2023-09-27 国立大学法人北海道大学 椎間板治療用組成物
JP7314207B2 (ja) 2016-03-23 2023-07-25 国立大学法人北海道大学 椎間板治療用組成物
US12478636B2 (en) 2016-03-23 2025-11-25 National University Corporation Hokkaido University Composition for treating intervertebral disc
JP2021154163A (ja) * 2016-03-23 2021-10-07 国立大学法人北海道大学 椎間板治療用組成物
WO2018159768A1 (ja) 2017-03-02 2018-09-07 持田製薬株式会社 線維軟骨組織損傷治療用組成物
US11426425B2 (en) 2017-03-02 2022-08-30 Mochida Pharmaceutical Co., Ltd. Composition for treating fibrocartilage tissue damage
JP7191007B2 (ja) 2017-03-02 2022-12-16 持田製薬株式会社 線維軟骨組織損傷治療用組成物
JPWO2018159768A1 (ja) * 2017-03-02 2019-12-26 持田製薬株式会社 線維軟骨組織損傷治療用組成物
JP7570809B2 (ja) 2017-03-07 2024-10-22 持田製薬株式会社 アルギン酸液剤
JP2023054083A (ja) * 2017-03-07 2023-04-13 持田製薬株式会社 アルギン酸液剤
WO2018164128A1 (ja) 2017-03-07 2018-09-13 持田製薬株式会社 アルギン酸液剤
JP7581398B2 (ja) 2017-03-07 2024-11-12 持田製薬株式会社 アルギン酸液剤
JPWO2018164128A1 (ja) * 2017-03-07 2020-04-16 持田製薬株式会社 アルギン酸液剤
EP4295838A2 (en) 2017-03-07 2023-12-27 Mochida Pharmaceutical Co., Ltd. Alginate liquid formulation
US11969437B2 (en) 2017-03-07 2024-04-30 Mochida Pharmaceutical Co., Ltd. Alginate liquid preparation
WO2019182015A1 (ja) 2018-03-22 2019-09-26 持田製薬株式会社 非ステロイド性抗炎症性化合物結合アルギン酸誘導体
JP2021109006A (ja) * 2020-01-14 2021-08-02 持田製薬株式会社 注入装置
US12491208B2 (en) 2020-01-14 2025-12-09 Mochida Pharmaceutical Co., Ltd. Combination and method for treating subject using alginate
WO2021145404A1 (ja) * 2020-01-17 2021-07-22 持田製薬株式会社 骨髄液を用いた軟骨損傷治療材
JP7607595B2 (ja) 2020-01-17 2024-12-27 国立大学法人北海道大学 骨髄液を用いた軟骨損傷治療材
JPWO2021145404A1 (ja) * 2020-01-17 2021-07-22

Also Published As

Publication number Publication date
BRPI0807739A2 (pt) 2014-06-03
CN104906126B (zh) 2019-05-28
EP3189859B8 (en) 2021-12-29
CA2912930A1 (en) 2008-08-28
US20100015102A1 (en) 2010-01-21
ES2637163T3 (es) 2017-10-11
JP5425134B2 (ja) 2014-02-26
CN101951969A (zh) 2011-01-19
BRPI0807739B1 (pt) 2018-06-26
CA2677436C (en) 2016-02-02
KR20090113849A (ko) 2009-11-02
AU2008217916A1 (en) 2008-08-28
JPWO2008102855A1 (ja) 2010-05-27
EP3189859B1 (en) 2021-10-13
IL200342A (en) 2015-03-31
IL200342A0 (en) 2010-04-29
EP3189859A1 (en) 2017-07-12
NZ578985A (en) 2011-12-22
US20130189231A1 (en) 2013-07-25
NZ596105A (en) 2012-08-31
CA2912930C (en) 2017-09-12
US8372394B2 (en) 2013-02-12
CA2677436A1 (en) 2008-08-28
EP2127687B1 (en) 2017-05-17
EP2127687A1 (en) 2009-12-02
CN101951969B (zh) 2015-06-03
IL230335A (en) 2015-07-30
US9216201B2 (en) 2015-12-22
EP2127687A4 (en) 2010-11-17
MX2009008760A (es) 2009-08-27
AU2008217916B2 (en) 2013-03-21
JP4740369B2 (ja) 2011-08-03
CN104906126A (zh) 2015-09-16
KR101440170B1 (ko) 2014-09-12
JP2011224378A (ja) 2011-11-10

Similar Documents

Publication Publication Date Title
WO2008102855A1 (ja) 軟骨疾患治療用組成物
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
MX2010004484A (es) Composicion para tratamiento de enfermedad de las articulaciones.
WO2010071826A3 (en) Methods for treating osteoclast-related disease, compounds and compositions thereof
WO2010151338A3 (en) Myostatin inhibitor enhancement of musculoskeletal repair
WO2015009991A3 (en) Methods, systems, and compositions for promoting bone growth
EA201070740A1 (ru) Способ лечения перелома кости антителами против склеростина
WO2007070547A3 (en) Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid
WO2006113864A3 (en) Oxindole compounds and their uses as therapeutic agents
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
WO2009045356A8 (en) Microrna compositions in the treatment of vegf-mediated disorders
WO2007144493A3 (fr) Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
TW200724543A (en) Heterocyclic compounds and their uses as therapeutic agents
ATE538775T1 (de) Ketorolac-tromethamin-zusammensetzungen zur behandlung oder prävention von schmerz
WO2007120485A3 (en) Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor
WO2011044523A3 (en) Compositions and methods for treating obesity
WO2010094734A3 (en) Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
WO2011028737A3 (en) Bisphosphonate compositions and methods for treating heart failure
WO2008073466A3 (en) Alpha b-crystallin as a therapy for inflammation
WO2011011706A3 (en) Methods and compositions for treating or preventing autoimmune diseases using immunomodulatory agents
MX2012001449A (es) Inhibidores de cinasas c-jun-n-terminales (jnk).
EP2716285A3 (en) New method for identifying compounds useful for treating and/or preventing diseases associated with bone loss
WO2010042212A3 (en) Methods for treating or preventing pain using spicamycin derivatives
WO2009140059A3 (en) Narcotic emulsion formulations for treatment of surgical pain
WO2007014253A3 (en) Method of treating or preventing tissue deterioration, injury or damage due to congestive heart failure

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880004925.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08720791

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2009500239

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 12311426

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2677436

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1488/MUMNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200342

Country of ref document: IL

Ref document number: 578985

Country of ref document: NZ

Ref document number: 2008217916

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020097016862

Country of ref document: KR

REEP Request for entry into the european phase

Ref document number: 2008720791

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008720791

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/008760

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008217916

Country of ref document: AU

Date of ref document: 20080221

Kind code of ref document: A

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: PI0807739

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090814